Fig. 3

EOFAZ ameliorated RMCs gliosis induced by HG. RMCs were treated with 30 mM HG in combination with EOFAZ (0.25, 0.5 and 1 μg/L) for 48 h. The percentage of RMCs in each phase of the cell cycle, including G1, S, and G2 phase, was detected by flow cytometry (a, b). Cell viability was analyzed via the MTT assay (c). Giemsa staining was used to analyze the pathological morphology in RMCs (×200) (d). qRT-PCR (e) and Western blot (f, g) were used to analyze mRNA or protein expression of GFAP and VEGF, respectively. Data are expressed as mean ± SEM. n = 3. **P < 0.01 vs. control group, ^#P < 0.05, ^##P < 0.01 vs. HG treated group